Recent Quotes (30 days)

You have no recent quotes
chg | %

Premaitha Health PLC news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

NIPT 8.91 +0.29 (3.35%)
price chart
Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo ...
Premaitha's CE-marked, non-invasive prenatal screening (NIPT) product, the IONA� test, runs on Thermo Fisher's two sequencing instruments, the Ion Proton and Ion Chef.
Thermo Fisher to Provide �5M Loan to Premaitha Health as Firm's H1 2016 ...  GenomeWeb
Thermo Fisher Scientific to Invest in Premaitha  Genetic Engineering & Biotechnology News (press release)
Analysts Consensus For Premaitha Health (LON:NIPT)
Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques.
Premaitha Health Plc Solid first year IONA sales; positive litigation update
Hardman & Co Report Premaitha Health Plc (LON:NIPT) uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests.
Premaitha Health PLC (NIPT) Given "Corporate" Rating at FinnCap  The Vista Voice
Premaitha Health PLC (NIPT) Given "Buy" Rating at Panmure Gordon  Web Breaking News
Premaitha Health PLC 134.1% Potential Upside Indicated by Panmure Gordon
Premaitha Health PLC with EPIC/TICKER LON:NIPT had its stock rating noted as 'Retains' with the recommendation being set at 'BUY' this morning by analysts at Panmure Gordon.
Paddy Power Plc (PAP) Now Covered by Credit Suisse  The Vista Voice
Vodafone Group Plc (VOD) Upgraded to "Buy" at Bank of America  Web Breaking News
Recent Research Analysts' Ratings Updates for Premaitha Health PLC (NIPT)
3/29/2016 - Premaitha Health PLC had its “buy” rating reaffirmed by analysts at Panmure Gordon. They now have a GBX 24 ($0.34) price target on the stock.
PEG Ratio (5 yr expected):
Premaitha Health PLC, a molecular diagnostic company, develops tests for non-invasive prenatal screening and other applications in the United Kingdom.
Premaitha Health to join AIM as it prepares to launch first product
Subject to ViaLogy shareholders approval later this month, the enlarged business will be re-named Premaitha Health PLC and will become a listed company on the AIM platform.
ViaLogy Buys Molecular Diagnostic Company But Struggles To  London South East
New Down's syndrome test likely after pharma reverse takeover  Financial Times
Related articles »  
Premaitha Health partners with Visional Medical to provide the IONA test to ...
Manchester, UK and Chennai, India - 3 February 2016 - Premaitha Health plc (AIM: NIPT, "Premaitha" or "the Company") developer of the IONA� test, the first CE-marked non-invasive prenatal screening (NIPT) product, has signed an agreement with ...
Premaitha Inks India Distribution Deal for Iona Prenatal Screening Test  GenomeWeb
Premaitha Health PLC bags tenth customer
Premaitha Health PLC (LON:NIPT) has landed a tenth customer for its IONA diagnostic, Europe's first CE-marked non-invasive DNA-based pre-natal test for Down's Syndrome.
Premaitha Health (LON:NIPT) New Price Targets
Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques.